Teva- Pharmaceutical Industries Ltd. - ADR

Teva- Pharmaceutical Industries Ltd. - ADR

TEVA

Get informed when a big investor buys or sells

+ Follow
Market Cap$41.13B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Teva- Pharmaceutical Industries Ltd. - ADRTeva- Pharmaceutical Industries Ltd. - ADR25.8-19%2.22.1

Earnings Call Q1 2026

April 29, 2026 - AI Summary

Strong Q1 performance; innovative portfolio driving growth - Revenue: $4.0B, down 1% (as reported), up 7% excluding Japan divestment and including generic REVLIMID. - Adjusted EBITDA: $1.1B (+2% YoY); Non-GAAP EPS: $0.53 (+2%). - Free cash flow: $200M (+76%); net debt/EBITDA: 2.42x. - Innovative brands were the key driver: +41% YoY to $578M, led by AUSTEDO (+41%), UZEDY (+62%), AJOVY (+35%). - Generics were softer: -13% globally mainly due to generic REVLIMID; however generics were flat excluding both Japan and REVLIMID, which management framed as “as expected.”
2026 outlook reaffirmed (key ranges) and margin trajectory remains on track - Teva reaffirmed 2026 guidance on an underlying basis excluding Emalex; acquisition treated as an asset deal with upfront cash booked as R&D/IP expense (per Eli). - Guidance highlights for 2026: - Non-GAAP gross margin: 54.5%–55.5% - Operating expenses: 27%–28% of revenue (with first half higher) - Free cash flow: $2.0B–$2.4B (no change) - Tax rate: 16%–19% (excluding Emalex) - Management expects gradual revenue increase through the year; channel/inventory dynamics may evolve (less-than-expected destocking in Q1). - Margins expected to ramp during the year; stable in Q4 vs Q3 due to anticipated AUSTEDO channel dynamics and pricing/order pattern ahead of IRA in Jan 2027.
Pivot to Growth strategy: transformation progress supports the 2027 30% operating margin target - Management reiterated the 2027 financial targets: mid-single digit revenue growth, non-GAAP operating income 30%, net debt/EBITDA <2x, cash-to-earnings 80%. - Operating margin path: ~26% in 2025 to 30% by 2027, supported by: - Continued mix shift to innovative/high-margin products - $700M savings from transformation programs targeting ~2/3 achieved by end of 2026. - Restructuring costs: already $205M recorded in 2025, ~$25M in Q1 2026, and ~$90M–$100M cash outflow expected in 2026.

Exclusive for Stockcircle Pro members

Sign upSign Up
$41.25

Target Price by Analysts

25.6% upsideTeva- Pharmaceutical Industries Target Price DetailsTarget Price
$15.28

Current Fair Value

53.5% downside

Overvalued by 53.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$41.13 Billion
Enterprise Value$54.29 Billion
Dividend Yield$- (-)
Earnings per Share$1.23
Beta0.86
Outstanding Shares1,156,000,000

Return

Return on Equity19.01%ROE
Return on Assets3.91%
Return on Invested Capital8.08%

Valuation & Multiples

P/E Ratio25.75P/E Ratio
PEG35.56PEG
Price to Sales2.19Price to Sales
Price to Book Ratio4.69Price to Book Ratio
Enterprise Value to Revenue3.13
Enterprise Value to EBIT25.36
Enterprise Value to Net Income34
Total Debt to Enterprise0.31
Debt to Equity2.05Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 13, 2026
EPS Estimate
$0.56
Average shareholder expectation
Revenue Estimate
$3.87 B
Average shareholder expectation

Next Earnings Call

Expected Date
July 29, 2026
EPS Estimate
$0.53
Average shareholder expectation
Revenue Estimate
$4.06 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.5768▼ 4.69%
Total Calls20,062,948▼ 34.65%
Total Puts11,572,900▼ 39.56%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %58.63%▼ 1.17%
Total Invested$20.16B▼ 6.01%
Investors Holding684▼ 10.00%

ESG Score

No data

About Teva- Pharmaceutical Industries Ltd.

CEO: Kaare Schultz

Relevant Senate Committees

Joint Committee on Taxation

This committee provides crucial analysis and revenue estimates for all tax legislation, directly influencing corporate tax structures and the overall tax burden on pharmaceutical companies like Teva, thus impacting profitability and investment decisions.

Finance

As the primary committee for taxation, trade, and entitlement spending, it directly impacts Teva through corporate tax policy, trade regulations, and, critically, Medicare pricing for pharmaceuticals, which significantly affects revenue.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA and NIH. Its oversight of drug approval processes, pharmaceutical R&D, and broader healthcare policy is a primary driver of success and regulation for Teva.

Judiciary

This committee's oversight of antitrust laws and intellectual property (patents) is critically important for Teva, influencing mergers, competition in the generic drug market, and the protection of its pharmaceutical innovations.